Trial purpose
Cancer treatment
Tumor type
Haematological
Age
18 - 130
Clinical summary
Summary
This is a modular dose confirmation and expansion study. Module 1 of this study will evaluate how safe, tolerable and effective AZD4573 is as monotherapy. Eligible participants will be split into three cohorts depending on their diagnosis, and all participants will receive AZD4573 as monotherapy via intravenous infusion. If AZD4573 monotherapy is found to have promising anti-cancer effectiveness in Module 1, an AZD4573 monotherapy Phase II expansion may be added.
Conditions
This trial is treating people with relapsed or refractory peripheral T-cell lymphoma and classical Hodgkins lymphoma
Eligibility
Inclusion
- Certain countries may require older age to be eligible for clinical trials. Follow the local laws and regulations regarding age requirement for participant eligibility.
-
Participants who are diagnosed with one of the following, as defined by the World Health Organisation:
- Peripheral T-cell Lymphoma
- Classical Hodgkin Lymphoma
- Eastern Cooperative Oncology Group performance status of ≤ 2.
-
Must have received at least 1 prior line of therapy for the treatment of current disease and have documented relapsed or refractory active disease requiring treatment, defined as:
- Recurrence of disease after response to prior line(s) of therapy, or
- Progressive disease after completion of or on the treatment regimen preceding entry into the study, or
- Disease which did not achieve an objective response (CR or PR) with prior therapy.
- Uric acid level < ULN at screening. If hyperuricaemia is present at screening, SoC therapy should be administered (including IV fluid and rasburicase or allopurinol) to reduce the uric acid levels to < ULN before the start of study intervention.
- Willing and able to participate in all required evaluations and procedures in this study protocol including receiving IV administration of study drug and being admitted, if required, for at least 24 hours during study drug administration.
- Fresh tumour tissue or archival tumour tissue must be confirmed to be available at screening.
-
Adequate haematologic function at screening.
- No growth factor support within 14 days prior to the date of the screening laboratory assessment. Growth factor support is not allowed during screening.
- No transfusions within 7 days prior to the date of the screening lab assessment.
- PTCL Only: All participants with PTCL must be willing and able to provide baseline bone marrow aspirate and/or biopsy no older than 3 months and agree to undergo post-treatment bone marrow biopsy when required to confirm response.
Additional Module 1 Inclusion Criteria
Prior lines of therapy:
Exclusion
Type of Participant and Disease Characteristics:
- PTCL only: Diagnosis of any of the following: Lymphoblastic/precursor T-cell lymphoma or leukaemia; T-cell prolymphocytic leukaemia; T-cell large granular lymphocytic leukaemia; Cutaneous T-cell lymphoma (eg, primary cutaneous type ALCL, mycosis fungoide/Sezary syndrome); Monomorphic epitheliotropic intestinal T-cell lymphoma.
Medical Conditions:
- With the exception of alopecia and neuropathy, presence of any unresolved non haematological toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment.
- Presence of, or history of, CNS lymphoma, leptomeningeal disease, or spinal cord compression.
-
History of prior non-haematological malignancy except for the following:
- Malignancy treated with curative intent and with no evidence of active disease present for more than 1 year prior to screening and felt to be at low risk for recurrence by treating physician.
- Adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled non-melanomatous skin cancer.
- Adequately treated carcinoma in situ without current evidence of disease.
-
Any evidence of:
- Severe or uncontrolled systemic disease (eg, severe hepatic impairment, interstitial lung disease [bilateral, diffuse, parenchymal lung disease]).
- Current unstable or uncompensated respiratory or cardiac conditions.
- Uncontrolled hypertension.
- Uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
- Anti-infective treatment (IV or oral) within 1 week before first dose of study drug.
- Known history of infection with HIV.
-
Serologic status reflecting active hepatitis B or C infection:
- Participants who are tested positive for hepatitis B surface antigen (HBsAg) will be excluded. Participants who are HBsAg-negative but hepatitis B core antibody (anti-HBc)-positive will need to have a negative hepatitis B virus (HBV) PCR result before enrolment. Those who are HBV PCR-positive will be excluded.
- Participants who are hepatitis C antibody positive will need to have a negative PCR result before enrolment. Those who are hepatitis C PCR-positive will be excluded.
-
Any of the following cardiac criteria:
- Resting QT interval corrected using Fridericia's formula (QTcF) ≥ 470 msec obtained from a single ECG.
- Any clinically important abnormalities in rhythm (except for participants with a pacemaker in place), conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block).
- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age.
- Documented confirmation and ongoing treatment of adrenal gland insufficiency or pancreatitis.
-
Undergone any of the following procedures or experienced any of the following conditions within 6 months prior to first dose:
- Coronary artery bypass graft
- Angioplasty
- Vascular stent
- Myocardial infarction
- Angina pectoris
- CHF (New York Heart Association Class ≥ 2)
- Ventricular arrhythmias requiring continuous therapy
- Atrial fibrillation, which is judged as uncontrolled by the treating physician
- Haemorrhagic or thrombotic stroke, including transient ischemic attacks or any other CNS bleeding
Inclusion
- You have had treatment, but your cancer has come back (relapsed or recurrent).
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
Exclusion
- You have been diagnosed with a prior or secondary type of cancer.
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
AstraZeneca
Scientific Title
A Modular Phase II, Open-label, Multicentre Study to Assess AZD4573 Efficacy and Safety as Monotherapy or in Combination With Anti-cancer Agents in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or Classical Hodgkin Lymphoma
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information